The Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) and Randomised Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trials did not report on the incidence of any bleeding [5, 6]. The gene discussed is F10; the disease is atrial fibrillation.